CME Presentations

HoFH Clinician-Patient Communication



  • Kathleen Byrne, MSN, CRNP, FNLA, CLS, FPCNA

    Kathleen Byrne, MSN, CRNP, FNLA, CLS, FPCNA

    Kathleen Byrne, MSN, CRNP, FNLA, CLS, FPCNA

    Cardiovascular Nurse Practitioner, Clinical Lipids Specialist

    Kathleen Byrne, MSN, CRNP is a cardiovascular nurse practitioner at the Johns Hopkins Medical Institutions in Baltimore, Maryland. She works in both adult and pediatric cardiology and cares for patients with lipid disorders and adults with congenital heart disease. She is a clinical lipid specialist, a fellow of the National Lipid Association, and a fellow of the Preventive Cardiovascular Nurses Association. She received her BSN from Villanova University and her MSN from the University of Pennsylvania in Philadelphia. She then returned to the University of Pennsylvania to complete her post- master’s work to become a tertiary care nurse practitioner.
  • Erin D. Michos,  MD, MHS

    Erin D. Michos, MD, MHS

    Erin D. Michos, MD, MHS

    Director of Women's Cardiovascular Health Research, Associate Director of Preventive Cardiology

    Erin D. Michos, MD is an associate professor of medicine within the Division of Cardiology at the Johns Hopkins School of Medicine in Baltimore, MD, with a joint appointment in the department of epidemiology at the Johns Hopkins Bloomberg School of Public Health. Dr. Michos is director of Women's Cardiovascular Health Research and associate director of preventive cardiology within the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease. Her research focuses on cardio-obstetrics and cardiovascular disease in women; advanced lipid disorders; risk prediction for cardiovascular disease including the use of coronary artery calcium scores, markers of inflammation, and other biomarkers; and obesity and cardiometabolic diseases.
  • Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA

    Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA

    Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA

    Professor of Medicine, Cardiology

    Dr. Pamela Morris is a professor of medicine and cardiology and holds the Paul V. Kramer endowed chair in cardiovascular disease prevention at the Medical University of South Carolina. She is the founder and director of the Seinsheimer Cardiovascular Health Program, and is a fellow of the American College of Cardiology (ACC), American Heart Association, American Society of Preventive Cardiology, and National Lipid Association. She served as vice chair of the ACC Annual Scientific Sessions in 2019 and 2020, and as chair in 2021 and 2022. She is associate editor of the Journal of the American College of Cardiology and will serve as a trustee with the ACC from 2022 to 2027.
  • Megan Suozzo

    Megan Suozzo

    Megan Suozzo

    Interview Participant - Individual with HoFH

CME Information

Global Logo PQH Logo
Homozygous Familial Hypercholesterolemia: Improving Outcomes and the Patient Perspective
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with American Society for Preventive Cardiology (ASPC).


This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.


This activity was released on November 8th, 2023 and is valid for 12 months. Requests for credit must be made no later than November 8th, 2024.


The educational design of this activity addresses the needs of cardiologists, endocrinologists, and primary care practitioners.


Establishing an early diagnosis of homozygous familial hypercholesterolemia (HoFH) is important to ensure prompt treatment, lower low-density lipoprotein cholesterol, and reduce risk of progressive atherosclerotic cardiovascular disease. However, many patients remain undiagnosed until advanced cardiovascular disease is present. HoFH is also a difficult-to-treat disorder, with most patients requiring multiple lipid-lowering therapies and many not achieving target LDL-C levels.

Join a cardiologist and a lipidologist to review recommended screening and diagnostic techniques for HoFH. Panelists will discuss new therapies and associated indications, including the selection and sequencing of HoFH treatments. Also, in order to align HCP and patient perspectives and goals, experts will share strategies to improve clinician-patient communication, while reacting to role-play videos of patients and clinicians discussing HoFH in point-of-care settings.


After completing this activity, the participant should be better able to:
  • Describe endorsed screening approaches and diagnostic criteria for HoFH
  • Characterize approaches for incorporating therapies for HoFH into a patient-centered management plan
  • Elucidate the mechanisms of action and efficacy and safety data for newer agents for HoFH, including emerging indications


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 1 hour to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship
Erin D. Michos, MD, MHS
Director of Women's Cardiovascular Health Research
Associate Director of Preventive Cardiology
Division of Cardiology
Johns Hopkins University School of Medicine
Consulting Fee (e.g., Advisory Board): Amgen, Amarin, Boehringer Ingelheim, Edwards Lifescience, Esperion, Metronic, Novartis, Novo Nordisk, Pfizer
Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA
Professor of Medicine, Cardiology
Paul V. Kramer Endowed Chair in Cardiovascular Disease Prevention
Director, Seinsheimer Cardiovascular Health Program
Trustee, American College of Cardiology
The Medical University of South Carolina
Contracted Research (Principal Investigators must provide information, even if received by the institution): Esperion
Kathleen H. Byrne, MSN, CRNP, FNLA, CLS, FPCNA
Cardiovascular Nurse Practitioner
Clinical Lipids Specialist
Johns Hopkins Medical Institutions
Nothing to disclose
Megan Suozzo
Interview Participant - Individual with HoFH
Nothing to disclose

The planners and managers at Global Education Group have no relevant financial relationships to disclose. 

The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support:

For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at